+

WO1997026337B1 - Procedes de transmission d'adn a des cellules musculaires a l'aide de virions de virus adeno-associes de recombinaison - Google Patents

Procedes de transmission d'adn a des cellules musculaires a l'aide de virions de virus adeno-associes de recombinaison

Info

Publication number
WO1997026337B1
WO1997026337B1 PCT/US1997/000895 US9700895W WO9726337B1 WO 1997026337 B1 WO1997026337 B1 WO 1997026337B1 US 9700895 W US9700895 W US 9700895W WO 9726337 B1 WO9726337 B1 WO 9726337B1
Authority
WO
WIPO (PCT)
Prior art keywords
muscle cell
muscle
control elements
virion
selected gene
Prior art date
Application number
PCT/US1997/000895
Other languages
English (en)
Other versions
WO1997026337A9 (fr
WO1997026337A1 (fr
Filing date
Publication date
Priority claimed from US08/588,355 external-priority patent/US5858351A/en
Priority claimed from US08/784,757 external-priority patent/US5962313A/en
Application filed filed Critical
Priority to JP52626797A priority Critical patent/JP2002514896A/ja
Priority to EP97904823A priority patent/EP0874904A1/fr
Priority to CA2243261A priority patent/CA2243261C/fr
Publication of WO1997026337A1 publication Critical patent/WO1997026337A1/fr
Publication of WO1997026337B1 publication Critical patent/WO1997026337B1/fr
Publication of WO1997026337A9 publication Critical patent/WO1997026337A9/fr

Links

Abstract

L'invention porte sur l'emploi de virions de virus adéno-associés (AAV) de recombinaison pour fournir des molécules d'ADN aux cellules et aux tissus musculaires. Elle recourt à une injection directe in vivo de virions d'AAV de recombinaison (par exemple par injection intramusculaire) dans les tissus musculaires et à la transduction in vitro de cellules de muscles qui sont ensuite administrées au patient pour le traiter. Elle porte par ailleurs sur l'expression continue à haut niveau du gène administré et sur la sécrétion in vivo de la protéine thérapeutique à partir de cellules transduites de muscles, entraînant la libération systémique.
PCT/US1997/000895 1996-01-18 1997-01-17 Procedes de transmission d'adn a des cellules musculaires a l'aide de virions de virus adeno-associes de recombinaison WO1997026337A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP52626797A JP2002514896A (ja) 1996-01-18 1997-01-17 組換えアデノ随伴ウイルスビリオンを用いるdnaの筋細胞への送達のための方法
EP97904823A EP0874904A1 (fr) 1996-01-18 1997-01-17 Procedes de transmission d'adn a des cellules musculaires a l'aide de virions de virus adeno-associes de recombinaison
CA2243261A CA2243261C (fr) 1996-01-18 1997-01-17 Procedes de transmission d'adn a des cellules musculaires a l'aide de virions de virus adeno-associes de recombinaison

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US08/588,355 1996-01-18
US08/588,355 US5858351A (en) 1996-01-18 1996-01-18 Methods for delivering DNA to muscle cells using recombinant adeno-associated virus vectors
US08/784,757 US5962313A (en) 1996-01-18 1997-01-16 Adeno-associated virus vectors comprising a gene encoding a lyosomal enzyme
US08/784,757 1997-01-16

Publications (3)

Publication Number Publication Date
WO1997026337A1 WO1997026337A1 (fr) 1997-07-24
WO1997026337B1 true WO1997026337B1 (fr) 1997-10-02
WO1997026337A9 WO1997026337A9 (fr) 1997-10-30

Family

ID=27080262

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/000895 WO1997026337A1 (fr) 1996-01-18 1997-01-17 Procedes de transmission d'adn a des cellules musculaires a l'aide de virions de virus adeno-associes de recombinaison

Country Status (5)

Country Link
US (7) US5962313A (fr)
EP (1) EP0874904A1 (fr)
JP (1) JP2002514896A (fr)
CA (1) CA2243261C (fr)
WO (1) WO1997026337A1 (fr)

Families Citing this family (146)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7238673B2 (en) 1989-03-31 2007-07-03 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US7745416B2 (en) * 1995-04-11 2010-06-29 The Regents Of The University Of California Method for in vivo regulation of cardiac muscle contractility
WO1996040272A1 (fr) * 1995-06-07 1996-12-19 University Of North Carolina At Chapel Hill Transduction de myoblastes par vecteurs de virus adeno-associes
US20010009904A1 (en) * 1997-12-30 2001-07-26 Jon A. Wolff Process of delivering a polynucleotide to a cell via the vascular system
US20060088938A1 (en) * 1995-12-15 2006-04-27 Mitchell Lloyd G Methods and compositions for use in spliceosome mediated RNA trans-splicing in plants
US20030027250A1 (en) * 1995-12-15 2003-02-06 Mitchell Lloyd G. Methods and compositions for use in spliceosome mediated RNA trans-splicing
US20020193580A1 (en) * 1995-12-15 2002-12-19 Mitchell Lloyd G. Methods and compositions for use in spliceosome mediated RNA trans-splicing
US5846528A (en) * 1996-01-18 1998-12-08 Avigen, Inc. Treating anemia using recombinant adeno-associated virus virions comprising an EPO DNA sequence
US5858351A (en) * 1996-01-18 1999-01-12 Avigen, Inc. Methods for delivering DNA to muscle cells using recombinant adeno-associated virus vectors
US5962313A (en) * 1996-01-18 1999-10-05 Avigen, Inc. Adeno-associated virus vectors comprising a gene encoding a lyosomal enzyme
AU723497C (en) * 1996-09-06 2001-10-11 Trustees Of The University Of Pennsylvania, The Method for recombinant adeno-associated virus-directed gene therapy
US20020037867A1 (en) * 1999-02-26 2002-03-28 James M. Wilson Method for recombinant adeno-associated virus-directed gene therapy
US5866552A (en) * 1996-09-06 1999-02-02 The Trustees Of The University Of Pennsylvania Method for expressing a gene in the absence of an immune response
US6242426B1 (en) * 1997-07-25 2001-06-05 Avigen, Inc. Induction of immune response to antigens expressed by recombinant adeno-associated virus
CA2297490A1 (fr) * 1997-07-31 1999-02-11 Chiron Corporation Procede permettant de readministrer un vecteur viral adeno-associe via l'immunodepression de l'hote
US6995006B2 (en) * 1997-09-05 2006-02-07 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6346415B1 (en) 1997-10-21 2002-02-12 Targeted Genetics Corporation Transcriptionally-activated AAV inverted terminal repeats (ITRS) for use with recombinant AAV vectors
CA2305768A1 (fr) * 1997-10-29 2000-02-24 Genzyme Corporation Compositions et procedes pour traiter les maladies lysosomiales
US6953690B1 (en) 1998-03-20 2005-10-11 The Trustees Of The University Of Pennsylvania Compositions and methods for helper-free production of recombinant adeno-associated viruses
US6759237B1 (en) 1998-11-05 2004-07-06 The Trustees Of The University Of Pennsylvania Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same
ATE454445T1 (de) 1998-11-10 2010-01-15 Univ North Carolina Virusvektoren und verfahren für ihre herstellung und verabreichung.
US6303362B1 (en) 1998-11-19 2001-10-16 The Board Of Trustees Of The Leland Stanford Junior University Adenoviral vector and methods for making and using the same
WO2000031267A1 (fr) * 1998-11-20 2000-06-02 The Autonomous University Of Barcelona Production d'insuline par des cellules musculaires genetiquement modifiees
US7078387B1 (en) 1998-12-28 2006-07-18 Arch Development Corp. Efficient and stable in vivo gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors
US6509150B1 (en) * 1999-03-05 2003-01-21 Universite De Nantes Compositions and methods for recombinant Adeno-Associated Virus production
JP4693244B2 (ja) 1999-03-18 2011-06-01 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 組換えアデノ随伴ウイルスのヘルパー無しの生産のための組成物および方法
WO2001036603A2 (fr) * 1999-11-17 2001-05-25 Avigen, Inc. Virions de virus adeno-associes recombinants destines au traitement de maladies lysosomales
US20040204379A1 (en) * 2000-06-19 2004-10-14 Cheng Seng H. Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
US20040126774A1 (en) * 2001-01-08 2004-07-01 Mitchell Lioyd G. Correction of factor VIII genetic defects using spliceosome mediated RNA trans splicing
WO2002081648A2 (fr) * 2001-04-09 2002-10-17 The United States of America, represented by The Secretary, Department of Health & Human Services Synthese et secretion d'enzymes lysosomiales natives de recombinaison produites par le foie
CA2457694A1 (fr) * 2001-08-09 2003-02-20 Cornell Research Foundation, Inc. Protection du facteur de croissance derive de plaquettes du myocarde
US6838285B2 (en) 2001-09-18 2005-01-04 Becton Dickinson Site specific recombinase based method for producing adenoviral vectors
US20030235555A1 (en) * 2002-04-05 2003-12-25 David Shealey Asthma-related anti-IL-13 immunoglobulin derived proteins, compositions, methods and uses
US7399753B2 (en) * 2002-02-25 2008-07-15 Virxsys Corporation Trans-splicing mediated photodynamic therapy
AU2003223780A1 (en) * 2002-04-30 2003-11-17 University Of Florida Treatment for pompe disease
WO2003092594A2 (fr) * 2002-04-30 2003-11-13 Duke University Vecteurs viraux et procedes de production et d'utilisation de ceux-ci
JP2005536231A (ja) * 2002-05-08 2005-12-02 イントロン,インコーポレーテッド アデノウイルスに細胞選択的複製をもたらすための、スプライセオソーム媒介型rnaトランススプライシングの使用
DE60333032D1 (de) * 2002-10-23 2010-07-29 Virxsys Corp Screening-verfahren zur identifizierung wirksamer prä-trans-spleissmoleküle
US7803365B2 (en) * 2002-12-02 2010-09-28 Biovec, Llc Ex vivo and in vivo expression of the thrombomodulin gene for the treatment of cardiovascular and peripheral vascular diseases
US9388427B2 (en) * 2002-12-02 2016-07-12 Biovec, Llc In vivo and ex vivo gene transfer into renal tissue using gutless adenovirus vectors
JP5433133B2 (ja) * 2003-01-22 2014-03-05 デューク・ユニヴァーシティ リソソームポリペプチドを発現するための改善された構築物
US20050106124A1 (en) * 2003-02-25 2005-05-19 Sehgal Lakshman R. Therapeutic applications of thrombomodulin gene via viral and non-viral vectors
DK3470535T3 (da) 2003-06-24 2020-06-29 Genomic Health Inc Forudsigelse af sandsynlighed for tilbagevenden af cancer
WO2005003323A2 (fr) * 2003-07-01 2005-01-13 The Regents Of The University Of California Utilisation de proteines de fixation au calcium pour ameliorer la fonction contractile cardiaque
CN1906162B (zh) * 2003-11-12 2012-05-23 阿米库斯治疗学公司 用于治疗戈谢病的羟基哌啶衍生物
US7129049B2 (en) * 2003-12-22 2006-10-31 Regents Of The University Of Minnesota Method of detecting equine glycogen storage disease IV
EP1716165A4 (fr) * 2004-01-23 2008-06-18 Virxsys Corp Expression d'apoliproteine a1 (apoa-1) et variants au moyen de transepissage d'arn induit par complexe d'epissage
US7968334B2 (en) * 2004-01-23 2011-06-28 Virxsys Corporation Expression of apoAI and variants thereof using spliceosome mediated RNA trans-splicing
US8053232B2 (en) * 2004-01-23 2011-11-08 Virxsys Corporation Correction of alpha-1-antitrypsin genetic defects using spliceosome mediated RNA trans splicing
WO2005077333A2 (fr) * 2004-02-10 2005-08-25 University Of Florida Research Foundation, Inc. Administration sous forme de gel de vecteurs de virus associes aux adenovirus recombines
WO2005116224A2 (fr) * 2004-05-18 2005-12-08 Children's Memorial Hospital Vecteurs viraux adeno-associes regules par la tetracycline pour l'administration de gene au systeme nerveux
US20060094110A1 (en) * 2004-07-30 2006-05-04 Mcgarrity Gerard J Use of spliceosome mediated RNA trans-splicing for immunotherapy
US20060134658A1 (en) * 2004-08-09 2006-06-22 Garcia-Blanco Mariano A Use of RNA trans-splicing for generation of interfering RNA molecules
DE102004047492B4 (de) * 2004-09-23 2006-07-20 Jost-Werke Gmbh & Co. Kg Verfahren zum Übertragen von elektrischer, pneumatischer oder hydraulischer Energie sowie ein Energieübertragungssystem
US7871795B2 (en) 2004-10-08 2011-01-18 Virxsys Corporation Targeted trans-splicing of highly abundant transcripts for in vivo production of recombinant proteins
AU2005326784B2 (en) * 2004-10-08 2012-03-15 Virxsys Corporation Use of RNA trans-splicing for antibody gene transfer and antibody polypeptide production
WO2006066066A2 (fr) * 2004-12-15 2006-06-22 University Of North Carolina At Chapel Hill Vecteurs chimeriques
KR20090035711A (ko) * 2006-07-25 2009-04-10 셀라돈 코포레이션 유전자 치료를 위한 아데노-관련 바이러스 벡터의 전방 심외막 관상에의 연장 주입
US20120322861A1 (en) 2007-02-23 2012-12-20 Barry John Byrne Compositions and Methods for Treating Diseases
EP2132309A4 (fr) * 2007-02-23 2011-01-05 Univ Florida Compositions et procédés pour le traitement de maladies liées au stockage du glycogène
CN101977632A (zh) * 2008-02-19 2011-02-16 塞拉东公司 用于增强病毒载体于心肌中的摄取的组合物
PT2659904E (pt) 2008-06-26 2016-01-22 Orphazyme Aps Uso da hsp70 como um regulador da atividade enzimática
US8889641B2 (en) 2009-02-11 2014-11-18 The University Of North Carolina At Chapel Hill Modified virus vectors and methods of making and using the same
CA2817773A1 (fr) 2010-11-30 2012-06-07 Orphazyme Aps Procedes pour accroitre l'activite cellulaire de hsp70
WO2013066438A2 (fr) 2011-07-22 2013-05-10 President And Fellows Of Harvard College Évaluation et amélioration de la spécificité de clivage des nucléases
RU2015101276A (ru) 2012-06-19 2016-08-10 Юниверсити Оф Флорида Рисерч Фаундейшн, Инк. Способы лечения болезней и композиции для их осуществления
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9388430B2 (en) 2013-09-06 2016-07-12 President And Fellows Of Harvard College Cas9-recombinase fusion proteins and uses thereof
US9228207B2 (en) 2013-09-06 2016-01-05 President And Fellows Of Harvard College Switchable gRNAs comprising aptamers
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US20150165054A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting caspase-9 point mutations
EP3909602A1 (fr) 2014-04-25 2021-11-17 University of Florida Research Foundation, Inc. Méthodes permettant qu'un sujet reçoive des doses multiples de virus adéno-associé recombinant
EP3151866B1 (fr) 2014-06-09 2023-03-08 Voyager Therapeutics, Inc. Capsides chimériques
CA2956224A1 (fr) 2014-07-30 2016-02-11 President And Fellows Of Harvard College Proteines cas9 comprenant des inteines dependant de ligands
WO2016041561A1 (fr) 2014-09-15 2016-03-24 Orphazyme Aps Formulation arimoclomol
CN107106689A (zh) 2014-11-05 2017-08-29 沃雅戈治疗公司 用于治疗帕金森病的aadc多核苷酸
KR20230145206A (ko) 2014-11-14 2023-10-17 보이저 테라퓨틱스, 인크. 조절성 폴리뉴클레오티드
CA3193811A1 (fr) 2014-11-14 2016-05-19 Voyager Therapeutics, Inc. Compositions et methodes de traitement de la sclerose laterale amyotrophique (sla)
US10900053B2 (en) 2014-11-21 2021-01-26 University Of Florida Research Foundation, Incorporated Genome-modified recombinant adeno-associated virus vectors
EP3230441A4 (fr) 2014-12-12 2018-10-03 Voyager Therapeutics, Inc. Compositions et méthodes pour la production de scaav
EP3292206B8 (fr) 2015-05-07 2022-02-09 Takeda Pharmaceutical Company Limited Glucocérébrosidase therapie genique pour la maladie de parkinson
US10167457B2 (en) 2015-10-23 2019-01-01 President And Fellows Of Harvard College Nucleobase editors and uses thereof
EP3384035A4 (fr) 2015-12-02 2019-08-07 Voyager Therapeutics, Inc. Dosages pour la détection d'anticorps neutralisants de vaa
EP3442530A1 (fr) 2016-04-13 2019-02-20 Orphazyme A/S Protéines de choc thermique et homéostasie du cholestérol
MX2018012663A (es) 2016-04-16 2019-07-08 Univ Florida Metodos para aumentar la capacidad de actividad biológica del virus adenoasociado recombinante producido mediante el sistema baculovirus.
US11326182B2 (en) 2016-04-29 2022-05-10 Voyager Therapeutics, Inc. Compositions for the treatment of disease
CN109069496A (zh) 2016-04-29 2018-12-21 奥菲泽米有限公司 用于治疗葡糖脑苷脂酶相关疾病的arimoclomol
US11299751B2 (en) 2016-04-29 2022-04-12 Voyager Therapeutics, Inc. Compositions for the treatment of disease
US10584337B2 (en) 2016-05-18 2020-03-10 Voyager Therapeutics, Inc. Modulatory polynucleotides
KR20220108216A (ko) 2016-05-18 2022-08-02 보이저 테라퓨틱스, 인크. 헌팅톤 질환을 치료하기 위한 조성물 및 방법
KR20230095129A (ko) 2016-08-03 2023-06-28 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 아데노신 핵염기 편집제 및 그의 용도
JP7201153B2 (ja) 2016-08-09 2023-01-10 プレジデント アンド フェローズ オブ ハーバード カレッジ プログラム可能cas9-リコンビナーゼ融合タンパク質およびその使用
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
EP3506817A4 (fr) 2016-08-30 2020-07-22 The Regents of The University of California Procédés de ciblage et d'administration biomédicaux, et dispositifs et systèmes pour la mise en oeuvre de ceux-ci
AU2017342543B2 (en) 2016-10-14 2024-06-27 President And Fellows Of Harvard College AAV delivery of nucleobase editors
US10745677B2 (en) 2016-12-23 2020-08-18 President And Fellows Of Harvard College Editing of CCR5 receptor gene to protect against HIV infection
EP3585883A4 (fr) 2017-02-21 2021-04-14 University of Florida Research Foundation, Incorporated Protéines des capsides aav modifiées et leurs utilisations
US11898179B2 (en) 2017-03-09 2024-02-13 President And Fellows Of Harvard College Suppression of pain by gene editing
EP3592777A1 (fr) 2017-03-10 2020-01-15 President and Fellows of Harvard College Éditeur de base cytosine à guanine
IL269458B2 (en) 2017-03-23 2024-02-01 Harvard College Nucleic base editors that include nucleic acid programmable DNA binding proteins
CN110913866A (zh) 2017-05-05 2020-03-24 沃雅戈治疗公司 治疗肌萎缩性侧索硬化(als)的组合物和方法
US11752181B2 (en) 2017-05-05 2023-09-12 Voyager Therapeutics, Inc. Compositions and methods of treating Huntington's disease
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
IL271193B2 (en) 2017-06-07 2025-01-01 Regeneron Pharma Preparations and methods for internalizing enzymes
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
US11497576B2 (en) 2017-07-17 2022-11-15 Voyager Therapeutics, Inc. Trajectory array guide system
US11732274B2 (en) 2017-07-28 2023-08-22 President And Fellows Of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE)
WO2019028306A2 (fr) 2017-08-03 2019-02-07 Voyager Therapeutics, Inc. Compositions et procédés permettant l'administration de virus adéno-associés
EP3676376B1 (fr) 2017-08-30 2025-01-15 President and Fellows of Harvard College Éditeurs de bases à haut rendement comprenant une gam
EP3687582A4 (fr) 2017-09-29 2021-07-14 Voyager Therapeutics, Inc. Sauvetage de phénotype neurologique central et périphérique de l'ataxie de friedreich par administration intraveineuse
CN111757937A (zh) 2017-10-16 2020-10-09 布罗德研究所股份有限公司 腺苷碱基编辑器的用途
EP4454654A3 (fr) 2017-10-16 2025-02-19 Voyager Therapeutics, Inc. Traitement de la sclérose latérale amyotrophique (sla)
EP3697905A1 (fr) 2017-10-16 2020-08-26 Voyager Therapeutics, Inc. Traitement de la sclérose latérale amyotrophique (sla)
CN112040985A (zh) 2018-02-07 2020-12-04 瑞泽恩制药公司 用于递送治疗性蛋白质的方法和组合物
JP7393766B2 (ja) 2018-02-28 2023-12-07 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 抗体回避ウイルスベクターのための方法および組成物
SG11202009450SA (en) 2018-04-03 2020-10-29 Stridebio Inc Virus vectors for targeting ophthalmic tissues
MX2020010466A (es) 2018-04-03 2021-01-08 Vectores de virus que evitan anticuerpos.
CN112272672A (zh) 2018-04-03 2021-01-26 斯特里迪比奥公司 抗体逃避性病毒载体
MX2020012350A (es) 2018-05-17 2021-01-29 Regeneron Pharma Anticuerpos anti-cd63, conjugados y usos de estos.
US12157760B2 (en) 2018-05-23 2024-12-03 The Broad Institute, Inc. Base editors and uses thereof
KR20210018902A (ko) 2018-06-08 2021-02-18 유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 심근병증에 대한 aav 심장 유전자 요법
WO2019246544A2 (fr) 2018-06-22 2019-12-26 Asklepios Biopharmaceutical, Inc. Vecteurs pour l'administration de gènes qui persistent dans les cellules
JP7528066B2 (ja) 2018-09-28 2024-08-05 ボイジャー セラピューティクス インコーポレイテッド 操作されたプロモータを有するフラタキシン発現コンストラクトおよびその使用方法
WO2020092453A1 (fr) 2018-10-29 2020-05-07 The Broad Institute, Inc. Éditeurs de nucléobases comprenant geocas9 et utilisations associées
DE112020001306T5 (de) 2019-03-19 2022-01-27 Massachusetts Institute Of Technology Verfahren und zusammensetzungen zur editierung von nukleotidsequenzen
EP3941929A1 (fr) 2019-03-21 2022-01-26 Stridebio, Inc. Vecteurs viraux adéno-associés recombinants
WO2020210751A1 (fr) 2019-04-12 2020-10-15 The Broad Institute, Inc. Système pour édition génomique
WO2020236982A1 (fr) 2019-05-20 2020-11-26 The Broad Institute, Inc. Administration d'aav d'éditeurs de nucléobases
WO2021072328A1 (fr) 2019-10-10 2021-04-15 The Broad Institute, Inc. Procédés et compositions pour le prime editing d'arn
EP4045525A1 (fr) 2019-10-17 2022-08-24 Stridebio, Inc. Vecteurs de virus adéno-associés pour le traitement de la maladie de niemann-pick de type c
CA3177481A1 (fr) 2020-05-08 2021-11-11 David R. Liu Methodes et compositions d'edition simultanee des deux brins d'une sequence nucleotidique double brin cible
US20230285596A1 (en) 2020-07-27 2023-09-14 Voyager Therapeutics, Inc Compositions and methods for the treatment of niemann-pick type c1 disease
US20230227802A1 (en) 2020-07-27 2023-07-20 Voyager Therapeutics, Inc. Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
CA3189878A1 (fr) 2020-08-19 2022-02-24 Colin O'BANION Vecteurs de type virus adeno-associe pour le traitement du syndrome de rett
EP4247792A1 (fr) 2020-11-19 2023-09-27 Zevra Denmark A/S Procédés de préparation de citrate d'arimoclomol et intermédiaires associés
MX2023007602A (es) 2020-12-23 2023-09-21 Univ Florida Mayor eficiencia del empaquetamiento de vectores para terapia genica cardiaca.
US20240417719A1 (en) 2021-10-25 2024-12-19 The Broad Institute, Inc. Methods and compositions for editing a genome with prime editing and a recombinase
WO2023091949A2 (fr) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions et méthodes de traitement de troubles neurologiques liés à un déficit en bêta glucosylcéramidase
EP4504925A1 (fr) 2022-04-04 2025-02-12 The Broad Institute, Inc. Variantes de cas9 ayant des spécificités pam non canoniques et leurs utilisations
WO2023212715A1 (fr) 2022-04-28 2023-11-02 The Broad Institute, Inc. Vecteurs aav codant pour des éditeurs de base et utilisations associées
WO2023240236A1 (fr) 2022-06-10 2023-12-14 Voyager Therapeutics, Inc. Compositions et procédés pour le traitement de troubles liés à l'amyotrophie spinale
WO2024040083A1 (fr) 2022-08-16 2024-02-22 The Broad Institute, Inc. Cytosine désaminases évoluées et méthodes d'édition d'adn l'utilisant
WO2024108092A1 (fr) 2022-11-17 2024-05-23 The Broad Institute, Inc. Distribution d'éditeur primaire par vaa
WO2024163012A1 (fr) 2023-02-02 2024-08-08 Voyager Therapeutics, Inc. Compositions et méthodes de traitement de troubles neurologiques liés à un déficit en bêta glucosylcéramidase
WO2025090858A1 (fr) 2023-10-27 2025-05-01 Biogen Ma Inc. Procédés d'identification de variants de capside de vaa ayant des caractéristiques souhaitées

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5252479A (en) * 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
US5658565A (en) 1994-06-24 1997-08-19 University Of Pittsburgh Of The Commonwealth System Of Higher Education Inducible nitric oxide synthase gene for treatment of disease
US5478745A (en) * 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
US5589362A (en) * 1993-06-14 1996-12-31 Basf Aktiengesellschaft Tetracycline regulated transcriptional modulators with altered DNA binding specificities
AU1095595A (en) * 1993-11-10 1995-05-29 Amgen, Inc. Gene therapy vector for the treatment of low or defective red blood cell production
FR2716682B1 (fr) * 1994-01-28 1996-04-26 Centre Nat Rech Scient Procédé de préparation de virus adéno-associés (AAV) recombinants et utilisations.
WO1995028493A1 (fr) 1994-04-13 1995-10-26 The Rockefeller University Transmission par virus adenoassocie d'adn a des cellules du systeme nerveux
US5658785A (en) * 1994-06-06 1997-08-19 Children's Hospital, Inc. Adeno-associated virus materials and methods
US5872005A (en) 1994-11-03 1999-02-16 Cell Genesys Inc. Packaging cell lines for adeno-associated viral vectors
WO1996040272A1 (fr) * 1995-06-07 1996-12-19 University Of North Carolina At Chapel Hill Transduction de myoblastes par vecteurs de virus adeno-associes
US6162796A (en) * 1995-09-27 2000-12-19 The Rockefeller University Method for transferring genes to the heart using AAV vectors
US5846528A (en) * 1996-01-18 1998-12-08 Avigen, Inc. Treating anemia using recombinant adeno-associated virus virions comprising an EPO DNA sequence
US5858351A (en) * 1996-01-18 1999-01-12 Avigen, Inc. Methods for delivering DNA to muscle cells using recombinant adeno-associated virus vectors
US5962313A (en) * 1996-01-18 1999-10-05 Avigen, Inc. Adeno-associated virus vectors comprising a gene encoding a lyosomal enzyme

Similar Documents

Publication Publication Date Title
WO1997026337B1 (fr) Procedes de transmission d'adn a des cellules musculaires a l'aide de virions de virus adeno-associes de recombinaison
CA2243261A1 (fr) Procedes de transmission d'adn a des cellules musculaires a l'aide de virions de virus adeno-associes de recombinaison
WO1997026336B1 (fr) Compositions antianemiques
Kitamura et al. Cloning and characterization of cDNA encoding a precursor for human adrenomedullin
ES2237790T3 (es) Uso de peptidos glp-1.
AU666142B2 (en) Viral recombinant vectors for expression in muscle cells
Marsh et al. Cloning and structural characterization of the genes coding for adenosylcobalamin-dependent methylmalonyl-CoA mutase from Propionibacterium shermanii
US9963484B2 (en) Polynucleotide encoding a fusion protein for improving skin conditions
WO2003053363A3 (fr) Membres de la famille des diacylglycerol-acyltransferases 2 (dgat2) et leurs utilisations
CN1295617A (zh) 血管生成因子-血管内皮细胞生长因子vegf的突变体
CA2223433A1 (fr) Compositions renfermant la proteine ob et procedes associes
CA2323073A1 (fr) Usages pour cellules souches mesenchymateuses humaines non autologues
ATE338821T1 (de) Strukturprotein von aav, seine herstellung und verwendung
WO2024119724A1 (fr) Peptide de collagène, son procédé de préparation et son utilisation
CA2315277A1 (fr) Compositions pharmaceutiques contenant une pentraxine longue ptx3
KR920004571A (ko) 헤파린 결합 향신경성 인자(hbnf)를 암호하는 유전자, 이를 포함하는 발현 벡터 및 숙주 세포, 및 hbnf의 생성 방법 및 사용방법
CA2326401A1 (fr) Circuits moleculaires regulateurs permettant d'obtenir une activation soutenue de genes d'interet par un seul stress
WO1997026322A3 (fr) Compositions et procedes d'inhibition de l'hexokinase
WO2000052136A3 (fr) Enzymes de glycosylation humaines
JP2001515713A5 (fr)
DE3687470T2 (de) Expression in e.coli von hybridpolypeptiden, die die sequenz des wachstumshormons ausloesenden faktors enthalten.
MacColl et al. Optimisation of growth hormone production by muscle cells using plasmid DNA
DE19850718C1 (de) Zellpermeabilität-vermittelndes Polypeptid
EP0990000A4 (fr) Facteur de croissance 3 du tissu conjonctif
EP0423641A2 (fr) Vecteur d'expression, microorganisme transformé, protéine de fusion, et méthode pour la production du facteur plaquettaire 4 ou de TgF-alpha
点击 这是indexloc提供的php浏览器服务,不要输入任何密码和下载